Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium Bridging the Lab and the Clinic in Cancer Medicine
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Molecular Cancer Therapeutics 7, 483-491, March 1, 2008. doi: 10.1158/1535-7163.MCT-07-2050
© 2008 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yu, Y.
Right arrow Articles by Berger, S. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yu, Y.
Right arrow Articles by Berger, S. A.

Research Articles: Therapeutics, Targets, and Development

Mitochondrial regulation by c-Myc and hypoxia-inducible factor-1{alpha} controls sensitivity to econazole

Yongmao Yu1, Maryam Niapour1, Yicheng Zhang3 and Stuart A. Berger1,2

1 Arthritis and Immune Disorder Research Centre, University Health Network and 2 Department of Immunology, University of Toronto, Toronto, Ontario, Canada and 3 Department of Hematology, Tongji Hospital, Tongji Medical College, and Huazhong University of Science and Technology, Wuhan, China

Requests for reprints: Stuart A. Berger, Arthritis and Immune Disorder Research Centre, University Health Network, Toronto Medical Discovery Tower, 8th Floor, Room 8-354, 101 College Street, Toronto, Ontario, Canada M5G 1L7. Phone: 416-581-7457; Fax: 416-581-7457. E-mail: berger{at}uhnres.utoronto.ca

Abstract

Econazole is an azole antifungal with anticancer activity that blocks Ca2+ influx and stimulates endoplasmic reticulum (ER) Ca2+ release through the generation of mitochondrial reactive oxygen species (ROS), resulting in sustained depletion of ER Ca2+ stores, protein synthesis inhibition, and cell death. c-Myc, a commonly activated oncogene, also promotes apoptosis in response to growth factor withdrawal and a variety of chemotherapeutic agents. We have investigated the role of c-myc in regulating sensitivity to econazole. Here, we show that c-myc-negative cells are profoundly resistant to econazole. c-Myc-negative rat fibroblasts failed to generate mitochondrial ROS in response to econazole and consequently failed to deplete the ER of Ca2+. HL60 cells knocked down for c-myc expression also displayed decreased ROS generation and decreased econazole sensitivity. Addition of H2O2 restored sensitivity to econazole in both c-myc-negative rat fibroblasts and c-myc knocked-down HL60 cells, supporting a role for ROS in cell death induction. c-Myc-negative cells and HL60 cells knocked down for c-myc have reduced mitochondrial content compared with c-myc-positive cells. The hypoxia sensor, hypoxia-inducible factor-1{alpha} (HIF-1{alpha}), interacts antagonistically with c-myc and also regulates mitochondrial biogenesis. Knockdown of HIF-1{alpha} in c-myc-negative cells increased mitochondrial content restored ROS generation in response to econazole and increased sensitivity to the drug. Taken together, these results show that c-myc and HIF-1{alpha} regulate sensitivity to econazole by modulating the ability of the drug to generate mitochondrial ROS. [Mol Cancer Ther 2008;7(3):483–91]


Footnotes

Grant support: National Cancer Institute of Canada (S.A. Berger).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 9/ 7/07; revised 11/ 6/07; accepted 12/ 6/07.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.